Despite the regulatory approval of new antiepileptic drugs (AED) over the past decade and the expansion of indications deemed suitable for epilepsy surgery, individuals with intractable seizures – roughly one in three epilepsy patients – still face a dearth of…
By Kelly Roman, Vice President of Fisher Wallace Labs On February 10, 2012, the FDA convened an advisory panel hearing on whether to reclassify cranial electrotherapy stimulation (CES) devices. Despite being a low-risk device, CES has lingered in Class 3…
Washington is such a fun town, replete as it is with smoke and mirrors. It appears that despite my earlier protests about the mixed-up priorities where NIH spending are concerned, our elected officials are aware of the coming deluge of…
Politics, economics, and NIH spending priorities By MARK McCARTY Medical Device Daily Washington Editor
